This content is from: European Union

Interview: Anand Grover of the Lawyers Collective

The Indian Supreme Court’s rejection of Novartis’s Glivec patent brought the increasingly tense debate about the balance between patent rights and access to medicines to the forefront. Anand Grover, who successfully represented the Cancer Patient Aid Association in the case, argues that the patent system may not be the best way to encourage drug research

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | One Week Trial